These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 17624988)
1. Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary. Jaishuen A; Berrios-Rivera JP; Sirisabya N; Zheng HG; Li Y; Kavanagh JJ Int J Gynecol Cancer; 2008; 18(2):379-83. PubMed ID: 17624988 [TBL] [Abstract][Full Text] [Related]
2. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. Garcia AA; Hirte H; Fleming G; Yang D; Tsao-Wei DD; Roman L; Groshen S; Swenson S; Markland F; Gandara D; Scudder S; Morgan R; Chen H; Lenz HJ; Oza AM J Clin Oncol; 2008 Jan; 26(1):76-82. PubMed ID: 18165643 [TBL] [Abstract][Full Text] [Related]
3. Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Jurado JM; Sánchez A; Pajares B; Pérez E; Alonso L; Alba E Clin Transl Oncol; 2008 Sep; 10(9):583-6. PubMed ID: 18796376 [TBL] [Abstract][Full Text] [Related]
4. [Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma]. Yuan GW; Wu LY; Yao HW; Hou JL; Li XG; Liu LY Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):710-3. PubMed ID: 20021871 [TBL] [Abstract][Full Text] [Related]
5. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. Penson RT; Dizon DS; Cannistra SA; Roche MR; Krasner CN; Berlin ST; Horowitz NS; Disilvestro PA; Matulonis UA; Lee H; King MA; Campos SM J Clin Oncol; 2010 Jan; 28(1):154-9. PubMed ID: 19917843 [TBL] [Abstract][Full Text] [Related]
7. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Wright JD; Secord AA; Numnum TM; Rocconi RP; Powell MA; Berchuck A; Alvarez RD; Gibb RK; Trinkaus K; Rader JS; Mutch DG Int J Gynecol Cancer; 2008; 18(3):400-6. PubMed ID: 17645510 [TBL] [Abstract][Full Text] [Related]
8. What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies? Cheng X; Moroney JW; Levenback CF; Fu S; Jaishuen A; Kavanagh JJ J Chemother; 2009 Nov; 21(5):566-72. PubMed ID: 19933049 [TBL] [Abstract][Full Text] [Related]
16. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407 [TBL] [Abstract][Full Text] [Related]
17. Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer? Ayhan A; Taskiran C; Yigit-Celik N; Bozdag G; Gultekin M; Usubutun A; Guler N; Yuce K Int J Gynecol Cancer; 2006; 16(2):484-9. PubMed ID: 16681715 [TBL] [Abstract][Full Text] [Related]